KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Taxes (2016 - 2025)

Emergent BioSolutions' Change in Taxes history spans 13 years, with the latest figure at -$6.3 million for Q4 2025.

  • For Q4 2025, Change in Taxes fell 90.91% year-over-year to -$6.3 million; the TTM value through Dec 2025 reached -$1.7 million, down 107.3%, while the annual FY2025 figure was -$1.7 million, 107.3% down from the prior year.
  • Change in Taxes reached -$6.3 million in Q4 2025 per EBS's latest filing, down from $6.2 million in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $79.7 million in Q4 2022 to a low of -$40.9 million in Q2 2022.
  • Average Change in Taxes over 4 years is $2.1 million, with a median of -$1.6 million recorded in 2024.
  • Peak YoY movement for Change in Taxes: tumbled 284.78% in 2023, then skyrocketed 3.650722201599999e+17% in 2025.
  • A 4-year view of Change in Taxes shows it stood at $79.7 million in 2022, then tumbled by 115.93% to -$12.7 million in 2023, then skyrocketed by 74.02% to -$3.3 million in 2024, then tumbled by 90.91% to -$6.3 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Change in Taxes are -$6.3 million (Q4 2025), $6.2 million (Q3 2025), and $6.8 million (Q2 2025).